Abstract

We analyzed the propensity of the HER3 receptor and its extracellular domain (ECD) to undergo ligand-independent self-association. The HER3-ECD, purified from Drosophila S2 cells, binds the EGF-like domain of heregulin (hrg) with a K(d) of 1.9 nM as measured by surface plasmon resonance (SPR) studies. In a gel shift assay, the HER3-ECD self-associates into a uniform, slowly migrating species in a concentration-dependent manner, starting at concentrations of <10 nM. In contrast to the HER3-ECD, the ECD from the related HER2 receptor does not oligomerize under the same conditions. The direct interaction of HER3-ECDs was also demonstrated by pull-down assays and SPR measurements under physiological salt conditions. This self-association of the HER3-ECD was reversed by the addition of hrg but not by EGF. The apparent equilibrium dissociation constant for the HER3-ECD self-association is 15 nM, based on SPR measurements. In this analysis, hrg blocks HER3-ECD self-association, and the addition of hrg during the dissociation phase resulted in an accelerated off rate. This finding suggests that hrg can bind to and disrupt preexisting HER3-ECD oligomers. Full-length HER3 likewise exhibited self-association. Under conditions where co-immunoprecipitation and cross-linking of HER2 and HER3 were stimulated by hrg, HER3 self-association and cross-linking were disrupted by hrg. The implication is that the self-association of HER3-ECD favors the formation of catalytically inactive complexes of the HER3 receptor. Binding of hrg releases HER3 which may then form signaling-competent HER3-HER2 heterodimers.

Keywords

Surface plasmon resonanceDissociation (chemistry)ChemistryBiophysicsReceptorExtracellularNeuregulinImmunoprecipitationLigand (biochemistry)BiochemistryBiologyNanoparticleMaterials scienceNanotechnology

Related Publications

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation

Abstract Gefitinib (Iressa, ZD1839), a quinazoline tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), is approved for patients with advanced non...

2004 Molecular Cancer Therapeutics 306 citations

Publication Info

Year
2000
Type
article
Volume
39
Issue
29
Pages
8503-8511
Citations
50
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

50
OpenAlex

Cite This

Ralf Landgraf, David Eisenberg (2000). Heregulin Reverses the Oligomerization of HER3. Biochemistry , 39 (29) , 8503-8511. https://doi.org/10.1021/bi000953+

Identifiers

DOI
10.1021/bi000953+